ImmuPharma PLC (AIM:IMM, OTC:IMMPF) (ImmuPharma PLC (AIM:IMM, OTC:IMMPF)) Chairman and CEO Tim McCarthy joins Proactive London's Katie Pilbeam to talk about their detailed corporate update announced to the market on Thursday last week.
After a busy few months since the board and management restructuring in August, McCarthy explains firstly why these changes were so important for the business model.
He delves deeper into the key progress accomplished over the last couple of months, starting with Lupuzor™ and the PK study, then the P140 platform itself focusing on autoimmunity & inflammation as well as some key disease indications they are now focused on developing.
Another key indication they are working on is CIDP which stands for Chronic Inflammatory Demyelinating Polyneuropathy – McCarthy outlines the disease and opportunities.
He also touches on the longstanding relationship with the CNRS and Prof. Sylviane Muller as well as partnering opportunities within a number of the key programs and the overall investment thesis of ImmuPharma.
